The aim of the project is to assess brain network dynamics, self-referential information processing and prosociality and learning following the modulation of the serotonin-system by serotonergic-psychoactive compounds.
Topic Healthy Subjects
Country Switzerland
Visit trial
Status
Active, not recruiting
Results Published
Start date
01 December 2020
End date
01 October 2021
Phase
Phase I
Design
Blinded
Type
Interventional
Generation
First
Participants
30
Sex
Male
Age
20- 40
Therapy
No
Trial Details
The aim of the project is to assess brain network dynamics, self-referential information processing and prosociality and learning following the modulation of the serotonin-system by serotonergic-psychoactive compounds.Trial Number NCT04716335
Papers
Ayahuasca-Inspired DMT/HAR Formulation Reduces Brain Differentiation Between Self and Other FacesThis secondary analysis of an RCT brain imaging (EEG) study (n=30) examines how DMT/HAR and Harmine alone affect face recognition and self-processing in healthy males using a visual oddball task. It finds DMT/HAR enhanced early visual processing while reducing neural differentiation between self and other faces at posterior sites, suggesting psychedelics reshape rather than erase self-boundaries while preserving socially meaningful representations.
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
This crossover RCT (n=31) investigates the effects of a novel ayahuasca-inspired formulation containing harmine and DMT in healthy male subjects. It finds that the combination of DMT and harmine, but not harmine alone, leads to a psychedelic experience with psychological insights, emotional breakthroughs, and low challenging experiences. The study reports positive persisting effects at 1- and 4-month follow-ups, with no changes in personality traits, psychological flexibility, general well-being, or increases in psychopathology.
Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy Participants
This secondary analysis of an RCT (n=31) evaluates a novel pharmaceutical formulation of DMT and harmine in healthy male volunteers. The study finds that intranasal DMT and buccal harmine (pharmahuasca) produce consistent pharmacokinetic profiles and safe, well-tolerated effects resembling ayahuasca, with subjective experiences lasting 2–3 hours. This formulation is proposed as a safer, standardised alternative for potential therapeutic use in mental health disorders.